Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial | Synapse
May 1, 2026
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
TV
Tuan Vu
AH
Ali A Habib
SJ
Saiju Jacob
See all
Key Points
Key points are not available for this paper at this time.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Vu et al. (Wed,) studied this question.
synapsesocial.com/papers/69f41bb4ef2b80c36f936b2d
https://doi.org/https://doi.org/10.1016/s0140-6736(26)00690-2